Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
1(11%)
Results Posted
17%(1 trials)
Terminated
2(22%)

Phase Distribution

Ph early_phase_1
1
11%
Ph phase_1
6
67%
Ph phase_2
2
22%

Phase Distribution

7

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
2(22.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (11.1%)
Phase 16 (66.7%)
Phase 22 (22.2%)

Trials by Status

completed667%
terminated222%
active_not_recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
active_not_recruitingphase_2

Effects of GRA in Patients With Type 1

NCT04779645
completedearly_phase_1

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

NCT05093517
completedphase_2

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

NCT03117998
completedphase_1

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

NCT04545411
terminatedphase_1

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

NCT04330625
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04779645Phase 2

Effects of GRA in Patients With Type 1

Active Not Recruiting
NCT05093517Early Phase 1

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Completed
NCT03117998Phase 2

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Completed
NCT04545411Phase 1

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Completed
NCT04330625Phase 1

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Terminated
NCT03919617Phase 1

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

Completed
NCT04253223Phase 1

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Terminated
NCT02455011Phase 1

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Completed
NCT02715193Phase 1

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9